Development
PROCEPT BioRobotics Corporation
PRCT
$62.91
-$2.14-3.29%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 81.55% | 89.63% | 104.52% | 105.46% | 117.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 81.55% | 89.63% | 104.52% | 105.46% | 117.60% |
| Cost of Revenue | 71.75% | 83.64% | 101.16% | 102.06% | 103.83% |
| Gross Profit | 91.58% | 95.54% | 107.86% | 109.10% | 133.74% |
| SG&A Expenses | 48.34% | 53.66% | 70.65% | 70.25% | 74.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.55% | 65.09% | 79.61% | 78.61% | 75.70% |
| Operating Income | -35.24% | -44.32% | -60.02% | -59.59% | -49.04% |
| Income Before Tax | -21.50% | -37.80% | -51.92% | -53.32% | -45.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.50% | -37.80% | -51.92% | -53.32% | -45.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.50% | -37.80% | -51.92% | -53.32% | -45.61% |
| EBIT | -35.24% | -44.32% | -60.02% | -59.59% | -49.04% |
| EBITDA | -35.28% | -45.89% | -63.44% | -63.52% | -53.19% |
| EPS Basic | -14.53% | -32.99% | 5.52% | 52.53% | 71.58% |
| Normalized Basic EPS | -18.94% | -28.83% | 8.49% | 54.10% | 72.64% |
| EPS Diluted | -14.53% | -32.99% | 5.52% | 52.53% | 71.58% |
| Normalized Diluted EPS | -18.94% | -28.83% | 8.49% | 54.10% | 72.64% |
| Average Basic Shares Outstanding | 6.50% | 3.94% | 25.36% | 70.98% | 170.93% |
| Average Diluted Shares Outstanding | 6.50% | 3.94% | 25.36% | 70.98% | 170.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |